AI Consensus Investment Thesis
Pfizer (PFE) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
BUY
Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.
1-Year
BUY$29
+5.4%+9.7% incl. dividends5-Year
BUY$38
+38.2%+68.2% incl. dividendsLatest flagship insight
Patent Expiration Abyss Meets Oncology Bridge as Operational Restructuring Defends Cash Flow
High consensus confirms foundational revenue faces significant patent expiration friction through 2028, offset by commercial antibody-drug conjugate momentum and structural cost rationalization. Crucially, underlying free cash flow stabilizes near eleven billion dollars, insulating the high-yield dividend despite heavy acquisition debt obligations.
This is the latest published deep-analysis batch. Audit published forecasts in full transparency
Superintelligence (Anthropologist), Universal Investor (Polymath), J.P. Morgan (Titan), Machiavelli (Insider), Warren Buffett (Value Purist), Ray Dalio (Strategist), Elon Musk (Visionary), Sherlock Holmes (Whistleblower), Michael Burry (Vulture). Some archetypes run in multiple modes, resulting in 14 advisors total.
Gemini
Claude
ChatGPTExecutive Summary
Dotted terms open concise definitions. Browse technical terms
If you invested $10,000 in Pfizer at the forecast anchor (2026-09-18): $16,816 in five years versus $13,892 for S&P 500 benchmark.
* Return is calculated incl. 4.0% net dividend yield for Pfizer.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView tableClose table
Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.
Swipe the table horizontally to read every column.
| Quarter | Target (USD) | Quarter return | Total return | Forecast rationale |
|---|---|---|---|---|
| Q4 2026 | 28.06 | +1.45% | +1.45% | Seasonal respiratory vaccine distributions alongside initial operational restructuring savings stabilize margins. Defensive institutional capital rotates into high-yielding healthcare equities, supporting modest multiple expansion despite restrictive central bank benchmark borrowing rates. |
| Q1 2027 | 28.45 | +1.37% | +2.84% | Full-year results separate non-cash impairment charges from recurring operating cash flows, reaffirming dividend coverage. Steady volume gains in acquired oncology antibody-drug conjugates counterbalance early international generic pricing pressures. |
| Q2 2027 | 28.71 | +0.93% | +3.80% | Initial statutory Medicare price adjustments introduce mild top-line friction, but accelerating manufacturing cost-realization milestones protect underlying operating profitability. Commercial oncology momentum preserves balanced, low-volatility price performance. |
| Q3 2027 | 29.16 | +1.58% | +5.44% | Pivotal oncology clinical readouts and positive cash-tax sunset relief reinforce operating cash flow. Reinvestment into Phase 3 metabolic trials absorbs capital, keeping quarterly equity valuation gains disciplined and measured. |
| Q4 2027 | 29.16 | 0.00% | +5.44% | Investor apprehension intensifies ahead of impending 2028 major patent expirations, inducing slight valuation compression. Year-end portfolio rebalancing and elevated debt refinancing costs partially offset ongoing administrative cost-reduction benefits. |
| Q1 2028 | 28.83 | -1.15% | +4.22% | Early generic erosion against core cardiovascular blockbusters arrives, initiating headline top-line contraction. While quarterly free cash flow remains sufficient to service debt, market participants aggressively discount near-term replacement uncertainty. |
| Q2 2028 | 28.38 | -1.57% | +2.59% | Peak patent-cliff anxiety compresses reported gross margins as generic small-molecule alternatives expand distribution. Free cash flow dividend coverage narrows, though verified run-rate operational savings prevent severe enterprise impairment. |
| Q3 2028 | 28.87 | +1.75% | +4.38% | Pivotal Phase 3 metabolic data updates and expanding oncology combination indications provide vital clinical validation. Operating margin stabilization confirms that multi-year restructuring programs are effectively cushioning legacy revenue attrition. |
| Q4 2028 | 29.63 | +2.63% | +7.13% | Commercial oncology volume expansion demonstrates durable standard-of-care market share gains. Management achieves significant debt retirement milestones, prompting contrarian value accumulation as the steepest phase of generic drag clears. |
| Q1 2029 | 30.46 | +2.80% | +10.13% | Annual financial reporting confirms the structural trough in earnings power has passed. Oncology and rare-disease product growth begins outpacing residual patent erosion, prompting upward revisions in forward cash-flow estimates. |
| Q2 2029 | 31.24 | +2.56% | +12.95% | Anticipation of regulatory filings for next-generation metabolic and oncology therapies expands institutional valuation multiples. Easing interest burdens from cumulative debt paydown directly lift bottom-line net profit margins. |
| Q3 2029 | 32.01 | +2.47% | +15.74% | Global commercial oncology sales achieve blockbuster velocity, demonstrating sustained pricing power across hospital channels. Robust operational cash conversion comfortably covers capital commitments, reinforcing corporate credit standing. |
| Q4 2029 | 32.85 | +2.63% | +18.78% | Cumulative enterprise restructuring reaches targeted run-rate savings, establishing a leaner operational cost baseline. Year-end institutional allocations reward predictable healthcare dividend yields amid late-cycle macroeconomic deceleration. |
| Q1 2030 | 33.68 | +2.50% | +21.75% | Commercial launch preparations for acquired metabolic therapies and expanded biologic indications trigger sell-side earnings upgrades. Operating margins stabilize firmly in the upper twenties following multi-year infrastructure rationalization. |
| Q2 2030 | 34.42 | +2.20% | +24.43% | Initial commercial uptake of newly approved therapies demonstrates expanding volume in chronic maintenance settings. Steady cash flows accelerate balance-sheet de-risking, lowering enterprise-wide financial leverage ratios. |
| Q3 2030 | 35.24 | +2.38% | +27.39% | Expanding international adoption for specialized antibody-drug conjugates solidifies therapeutic leadership. Rising returns on invested capital prompt equity analysts to adjust forward terminal valuation multiples upward. |
| Q4 2030 | 36.03 | +2.24% | +30.24% | Operational results highlight sustained revenue recovery, with organic biopharma growth fully compensating for past patent losses. Enhanced balance-sheet flexibility allows management to evaluate renewed share repurchases alongside distributions. |
| Q1 2031 | 36.85 | +2.30% | +33.24% | Commercial execution across oncology and cardiometabolic divisions delivers consistent quarterly earnings beats. Normalized operating margins extinguish historical market skepticism, driving steady capital accumulation among diversified funds. |
| Q2 2031 | 37.46 | +1.64% | +35.42% | High-margin specialty biologic franchises insulate enterprise cash generation from residual small-molecule generic commoditization. Reliable free cash flow conversion comfortably funds ongoing clinical reinvestment and shareholder payouts. |
| Q3 2031 | 38.23 | +2.06% | +38.21% | The five-year transition concludes with modernized clinical pipelines establishing durable proprietary market exclusivity. Terminal valuation multiples reach equilibrium, rewarding long-term capital with substantial intrinsic value realization. |
The central investment debate hinges on an operational sequencing mismatch: approximately seventeen billion dollars in mature revenues face statutory patent expiries and Medicare pricing concessions through 2028, while acquired oncology pipelinesoncology pipelineOncology pipeline refers to the portfolio of cancer-related drug candidates, programs, or studies progressing through research and development stages.View full glossary entry and metabolic candidates mature on a delayed timeline. The market excessively discounts this valley by extrapolating top-line erosion into permanent capital destructioncapital destructionA lasting loss of invested capital caused by poor returns, impairment, dilution, or uneconomic investment.View full glossary entry, pricing shares at a single-digit forward adjusted earnings multipleearnings multipleThe ratio of share price to earnings per share used to determine stock valuation.View full glossary entry. In reality, ten billion dollars in enterprise-wide restructuring, the sunset of legacy tax obligations, and mid-teens operational growth in commercialized biologics establish a durable free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry floor near eleven billion dollars, insulating corporate liquidity. The strongest counterargument emphasizes capital allocationcapital allocationThe decision process for directing capital among operations, investment, acquisitions, debt repayment, dividends, and share repurchases.View full glossary entry fragility under elevated interest rates. Gross debt exceeding sixty billion dollars combines with a rigid nine-point-eight-billion-dollar dividend commitment, leaving minimal cushion for clinical trial failures or aggressive biosimilar pricing erosion.
Key insights
- Sustained free cash flow yieldfree cash flow yieldFree cash flow divided by market value, showing cash generation relative to the asset price.View full glossary entry near seven percent establishes an asymmetric margin of safetymargin of safetyThe difference between an estimated intrinsic value and the purchase price, intended to allow for uncertainty or analytical error.View full glossary entry against small-molecule generic commoditizationcommoditizationThe process where services become indistinguishable, leading to price-based competition and severe margin erosion.View full glossary entry.
- Acquired antibody-drug conjugate scaling structurally shifts enterprise gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry above seventy percent, replacing decaying chemical revenues with high-barrier biologic pricing.
- Balance-sheet de-risking remains the gating factor for multiple expansionmultiple expansionAn increase in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry, as debt amortization takes strict precedence over opportunistic share buybacks.
The company is navigating a major transition as several older blockbuster drugs lose patent protection and face generic competition over the next three years. Wall Street worries this revenue drop will overwhelm the business and jeopardize its high dividend yielddividend yieldA financial ratio showing how much a company pays out in dividends each year relative to stock price.View full glossary entry. However, aggressive cost-cutting programs and rapid sales growth in newly acquired cancer treatments are stabilizing baseline cash generation, creating a solid earnings foundation. While high debt from past acquisitions leaves little room for error if new drug trials stumble, the business produces enough cash to defend operations.
Key insights
- Strong sales of specialized cancer medicines are steadily replacing lost revenues from expiring older drugs.
- Massive multi-billion-dollar cost reduction programs are successfully protecting company profit marginsprofit marginsProfit margins measure the share of revenue retained as profit after covering specified costs, expressed as a percentage.View full glossary entry during this transitional period.
- Dependable annual cash flow keeps the attractive dividend supported while management gradually pays off corporate debt.
Deep Dive
Prevailing market consensus treats the equity as an uninvestable value trapvalue trapA stock that appears cheap based on valuation metrics but remains stagnant due to fundamental business deterioration.View full glossary entry caught in an irreversible post-pandemic hangover. Investors assume an impending seventeen-billion-dollar patent cliffpatent cliffA period when important patents expire and revenue may fall rapidly because generic or biosimilar competition enters.View full glossary entry will crush operating income while sixty billion dollars in acquisition debt and an unyielding dividend exhaust liquidity. The crowd anchors on recent clinical write-downs, pricing in perpetual structural declinestructural declineA long-term weakening trend caused by persistent business or industry headwinds.View full glossary entry and viewing the high yield as an impending dividend cut.
Paywalled preview begins: Deep Dive: detailed analysis
From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Opinions—and what could close the gap?
Market Narrative
What does the market currently expect? Prevailing market consensus treats the equity as an uninvestable value trapvalue trapA stock that appears cheap based on valuation metrics but remains stagnant due to fundamental business deterioration.View full glossary entry caught in an irreversible post-pandemic hangover. Investors assume an impending seventeen-billion-dollar patent cliffpatent cliffA period when important patents expire and revenue may fall rapidly because generic or biosimilar competition enters.View full glossary entry will crush operating income while sixty billion dollars in acquisition debt and an unyielding dividend exhaust liquidity. The crowd anchors on recent clinical write-downs, pricing in perpetual structural declinestructural declineA long-term weakening trend caused by persistent business or industry headwinds.View full glossary entry and viewing the high yield as an impending dividend cut.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd underestimates fundamental value by misinterpreting temporary GAAP impairments as permanent operational cash erosion. The analytical edge rests on recognizing that non-COVID commercial revenues are expanding at mid-single digits, supported by high-margin oncology biologics and multi-billion-dollar cost-realignment programs. Crucially, the final repatriation-tax payment removes an ongoing cash drain. This cash-generation floor protects dividend coverage and debt servicing, refuting the market's linear extrapolation of financial decay.
Repricing Catalyst
What could make the market recognize and close that gap? Market repricing will trigger as consecutive reporting cycles through late 2027 demonstrate that realized cost savings and commercial oncology expansion keep trailing free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry safely above dividend commitments despite initial Medicare price concessions. Pivotal Phase 3 clinical readouts for monthly metabolic maintenance candidates will further dismantle the structural declinestructural declineA long-term weakening trend caused by persistent business or industry headwinds.View full glossary entry thesis, forcing sell-side analysts to revise depressed terminal cash-flow multiples upward.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Fear
- Volatility
- Moderate
- Cycle position
- Stabilization
Sentiment aligns around deep prevailing skepticism and trough valuation multiples. The primary disagreement centers on cycle duration: whether current trading marks an orderly fundamental bottoming phase or the precursor to forced dividend restructuring under generic pressure.
Macro Regime Fit
Does the current market environment support the thesis? The prevailing monetary regimemonetary regimeThe prevailing framework of central-bank policy, interest rates, money creation, and exchange-rate management.View full glossary entry of restrictive policy rates near four percent and elevated sovereign yields creates refinancing friction for the company's sixty-billion-dollar debt burden. However, non-cyclical pharmaceutical demand provides robust pricing insulation against broader economic deceleration, making the defensive six-percent cash distribution an attractive haven during macroeconomic volatility.
Advisor Disagreement
What do our AI Advisors disagree about most? The decisive analytical dispute centers on cash-flow durability versus patent-cliff velocity through 2028. Bullish perspectives argue that eleven billion dollars in recurring free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry, supported by structural cost cuts and oncology growth, easily bridges the transition until metabolic pipelines commercialize. Conversely, bearish models assert that rapid generic erosiongeneric erosionThe loss of market share and revenue as patents expire and cheaper generic alternatives enter the market.View full glossary entry across cardiovascular lines will overwhelm operational savings, leaving insufficient to cover both debt service and nearly ten billion dollars in annual dividends. Monitoring quarterly non-COVID commercial revenue growth against dividend coverage through 2027 will definitively resolve this debate.
Base-Case Forces
Event Risk ScoreLow38/100Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Commercial antibody conjugate oncology scaling | Competitive Positioning | +20% | +22% | Integration of acquired antibody-drug conjugates establishes a dominant specialty oncology infrastructure led by Padcev and Adcetris expanding into first-line indications. This biologics portfolio commands durable patent exclusivity extending well into the 2030s. Generating double-digit volume expansion across global cancer centers, this franchise expands gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry and directly replaces maturing small-molecule revenue streams. |
| Enterprise manufacturing and operational restructuring | Operational Efficiency | +16% | +20% | Management is methodically executing cumulative multi-year net cost reductions exceeding seven billion dollars across administrative, research, and manufacturing nodes. Streamlining post-pandemic operating footprints permanently lowers enterprise break-even thresholds. This expenditure discipline insulates operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry above twenty-five percent, preserving recurring cash generation to fully defend dividend commitments through the patent expiration transition. |
| Non-COVID commercial portfolio volume expansion | Sector And Industry | +12% | +14% | Underlying commercial therapies demonstrate consistent four-to-seven percent operational volume growth, driven by specialty cardiovascular, migraine, and pneumococcal vaccine lines. Aging global demographics sustain non-cyclical institutional prescription demand, decoupling fundamental product consumption from broader macroeconomic turbulence and providing a reliable revenue baseline of approximately sixty billion dollars annually. |
| Legacy cash tax obligation sunset | Capital Allocation | +10% | +0.0% | The conclusion of multi-year repatriation tax installments removes a substantial annual cash obligation from the balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry starting in 2027. This regulatory sunset directly enhances recurring free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry retention without altering reported GAAP operating income, widening the safety buffer for dividend distributions and accelerating post-acquisition debt amortization. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Multi-blockbuster patent cliffpatent cliffA period when important patents expire and revenue may fall rapidly because generic or biosimilar competition enters.View full glossary entry revenue chasm | Sector And Industry | -20% | -26% | Impending loss of exclusivityloss of exclusivityRefers to the expiration of patent protection leading to generic or biosimilar competition for key drugs.View full glossary entry across core revenue pillars between 2026 and 2028 exposes approximately seventeen billion dollars in high-margin sales to generic competition. Rapid erosion across Eliquis, Ibrance, and Xtandi eliminates substantial operating profit. This structural headwind depresses top-line growth, requiring aggressive pipeline commercialization simply to maintain stable enterprise earning power. |
| Statutory Medicare price negotiation compression | Regulatory | -11% | -13% | Mandatory drug price setting under the Inflation Reduction Act imposes statutory discounts on key commercial medicines, led by Eliquis starting in 2026. Administrative price ceilings compress gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry across Medicare Part D populations, permanently curtailing historical pharmaceutical pricing flexibility and accelerating cash-flow deterioration ahead of formal generic entry. |
| Debt refinancingdebt refinancingReplacing existing debt with new borrowing, often to change maturity, interest cost, currency, or covenants.View full glossary entry friction under tight policy | Macroeconomic And Macrofinancial | -10% | -11% | Funded debt exceeding sixty billion dollars following major acquisitions faces elevated refinancing rates under restrictive central bank policies. Higher debt-service carrying costs consume critical cash flow, depressing net earnings recovery and severely restricting capital allocationcapital allocationThe decision process for directing capital among operations, investment, acquisitions, debt repayment, dividends, and share repurchases.View full glossary entry flexibility for discretionary share repurchases or additional bolt-on business development. |
| Pipeline reinvestment burden and late attrition | Innovation And Product | -8.0% | -10% | Replacing exhausted blockbusters requires expending nearly twelve billion dollars annually in clinical research amidst inherent biological attrition risks. High-profile trial failures, such as recent non-cash asset impairments, destroy invested capital and delay commercial replacement timelines, reinforcing market skepticism regarding internal research and development productivity. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Forced dividend reduction under cash strain | 24% | -28% | Should patent erosion outpace pipeline commercialization while elevated interest expenses squeeze free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry below eight billion dollars, the board could be forced to reduce the dividend payout. Cutting distributions would trigger widespread institutional income-fund liquidation, causing an immediate, severe derating of equity multiples toward tangible book valuetangible book valueThe net asset value of a company calculated by subtracting intangible assets from total equity.View full glossary entry. |
| Late-stage oncology trial confirmatory failures | 22% | -24% | Pivotal Phase 3 confirmatory trials for core acquired antibody-drug conjugates could miss overall survival endpoints or exhibit unexpected toxicities by 2028. Such setbacks would force massive non-cash goodwill impairmentsgoodwill impairmentsAccounting write-downs occurring when the value of an acquired asset falls below its book value.View full glossary entry, dismantle the primary post-cliff replacement narrative, and permanently depress terminal valuationterminal valuationTerminal valuation is the estimated value of an asset or business beyond the explicit forecast period in a discounted cash flow model.View full glossary entry multiples across institutional research. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Monthly metabolic maintenance clinical breakthrough | 32% | +32% | Pivotal Phase 3 trials could establish acquired metabolic candidate MET097 or berobenatide as a premier once-monthly obesity maintenance therapy by 2028. Demonstrating competitive weight loss with superior patient persistence would capture significant share in a hundred-billion-dollar market, injecting multi-billion-dollar peak sales that completely overcome patent cliffpatent cliffA period when important patents expire and revenue may fall rapidly because generic or biosimilar competition enters.View full glossary entry drag. |
| Accelerated pan-tumor oncology label expansions | 30% | +24% | Key antibody-drug conjugates could secure expedited regulatory approvals across broader first-line indications in lung, breast, and solid tumors by late 2027. Unlocking large patient cohorts ahead of schedule would accelerate commercial oncology revenues past fifteen billion dollars annually, catalyzing immediate multiple expansionmultiple expansionAn increase in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry across institutional models. |
Company Financial Analysis
Pfizer Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
AI Review
Pfizer's financial story is one of operational stabilization following the post-pandemic vaccine unwind. Headline revenue stabilized near sixty-three point seven billion dollars for the trailing twelve months through mid-2026, demonstrating that non-COVID medicines are growing steadily. Although accounting results showed a net loss in the second quarter of 2026 due to a four-point-three-billion-dollar non-cash clinical trial impairment, core operating income remained resilient at nearly sixteen billion dollars. This gap reveals that actual cash generation is significantly healthier than reported net losses suggest. Trailing free cash flow reached eleven billion dollars, providing crucial liquidity to self-fund operations and protect shareholder distributions as legacy patent expirations approach.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 62.6B | USD 7.8B | USD 9.1B |
| 2024 | USD 63.6B | USD 8B | USD 9.8B |
| 2023 | USD 59.6B | USD 2.1B | USD 4.8B |
| 2022 | USD 100.3B | USD 31.4B | USD 26B |
| 2021 | USD 81.3B | USD 22.1B | USD 29.9B |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | 18.2x | TTM | Native | USD / USD |
| 2024 | 18.9x | TTM | Native | USD / USD |
| 2023 | 76.3x | TTM | Native | USD / USD |
| 2022 | 9.4x | Annual | Native | USD / USD |
| 2021 | 15.4x | Annual | Native | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
AI Review
Profitability is rebounding after absorbing pandemic-related disruptions. Gross margins expanded to seventy point three percent in fiscal 2025, recovering from fifty point nine percent in 2023 as low-margin vaccine inventories cleared and sales shifted toward high-margin cancer biologics. Operating margins stabilized near twenty-five percent, directly supported by ongoing corporate cost-reduction programs. This margin pattern demonstrates underlying pricing power across specialized treatments. Enterprise restructuring initiatives targeting billions in cumulative operational savings provide vital operating leverage. This disciplined cost containment creates a durable cushion that protects profitability even as mature small-molecule drugs encounter generic price competition.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD 15.4B | 24.7% | 12.4% |
| 2024 | USD 16.5B | 25.9% | 12.6% |
| 2023 | USD 5.3B | 8.9% | 3.6% |
| 2022 | USD 37.5B | 37.4% | 31.3% |
| 2021 | USD 20.8B | 25.6% | 27.2% |
Balance sheet and leverage
AI Review
The balance sheet carries substantial obligations from past debt-financed acquisitions, with funded debt standing near sixty billion dollars against eighty-six point five billion dollars in equity. This leverage results in a debt-to-equity ratio of zero point seven eight and interest coverage near three point eight times in fiscal 2025. While manageable, this debt burden limits discretionary share buybacks. Crucially, solvency remains safeguarded by strong liquidity and healthy operational cash flow. Well-staggered debt maturities prevent immediate refinancing crises, though paying nearly ten billion dollars in annual dividends consumes most available cash. Management must maintain disciplined debt repayment to preserve investment-grade credit ratings.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | USD 67.4B | USD 13.6B | USD 66.3B net debt | 1.16x |
| 2024 | USD 67B | USD 20.5B | USD 66B net debt | 1.17x |
| 2023 | USD 75B | USD 12.7B | USD 72.2B net debt | 0.91x |
| 2022 | USD 35.8B | USD 22.7B | USD 34.5B net debt | 1.22x |
| 2021 | USD 38.4B | USD 31.1B | USD 35.1B net debt | 1.40x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
AI Review
Management has exercised strict capital discipline by curtailing physical construction and factory expansions. Capital expenditures consumed roughly four point two percent of revenues in 2025, freeing up valuable cash to defend the balance sheet. Instead, financial firepower is concentrated directly in research laboratories, where nearly twelve billion dollars was committed to research and development in 2025. This spending profile demonstrates a clear corporate choice: avoid sinking money into unnecessary physical infrastructure while aggressively funding high-yield clinical trials. By prioritizing advanced cancer therapies and metabolic drug candidates, management aims to ensure pipeline renewals replace expiring revenues without requiring dilutive external financing.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 2.6B | USD 12B |
| 2024 | USD 2.9B | USD 10.7B |
| 2023 | USD 3.9B | USD 10.6B |
| 2022 | USD 3.2B | USD 11.4B |
| 2021 | USD 2.7B | USD 13.8B |
Quarterly Forecast Scenarios
Pfizer Averaged Consensus Scenarios
One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.
Scroll to view all columns
| Quarter | Bear case (USD) | Base case (USD) | Bull case (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|
| $26.83 | $28.13 | $28.49 | $750.26 | |
| $26.84 | $28.58 | $29.63 | $736.44 | |
| $25.49 | $28.89 | $30.22 | $743.40 | |
| $24.47 | $29.40 | $31.43 | $755.15 | |
| $23.74 | $29.46 | $31.75 | $776.22 | |
| $22.32 | $29.31 | $32.70 | $787.13 | |
| $20.31 | $29.04 | $32.04 | $802.83 | |
| $19.49 | $29.62 | $33.00 | $812.05 | |
| $19.88 | $30.41 | $33.66 | $839.18 | |
| $20.48 | $31.23 | $34.67 | $850.50 | |
| $21.30 | $32.04 | $36.05 | $872.39 | |
| $21.94 | $32.82 | $37.13 | $885.51 | |
| $22.82 | $33.66 | $38.61 | $909.56 | |
| $23.50 | $34.52 | $39.39 | $916.13 | |
| $24.21 | $35.28 | $41.36 | $936.51 | |
| $24.93 | $36.12 | $42.60 | $947.34 | |
| $25.43 | $36.96 | $44.30 | $969.59 | |
| $26.19 | $37.80 | $45.19 | $979.99 | |
| $26.72 | $38.47 | $46.99 | $999.60 | |
| $27.25 | $39.25 | $48.40 | $1,012 |
Behind the synthesis
How each opinion shapes the consensus
The independently supported consensus reveals an enterprise navigating an operational valley: pandemic windfall contraction has concluded, but impending loss of exclusivity across cornerstone cardiovascular and oncology therapies creates a severe top-line revenue gap between 2026 and 2028. Correlated assumptions across several reports treat commercial oncology expansion and multi-billion-dollar cost realignment as guaranteed complete offsets, occasionally downplaying trial execution hurdles. The strongest contrarian case convincingly demonstrates that annual dividend commitments of nearly ten billion dollars leave razor-thin free cash flow coverage when combined with debt refinancing friction near five percent yields. However, claims predicting an imminent dividend reduction or catastrophic legal settlements lack primary evidentiary support, given that non-COVID revenues are expanding at mid-single digits and the repatriation tax sunset provides tangible cash-retention relief. Weights are allocated to prioritize empirical SEC disclosure rigor, causal consistency, and precise multi-year operational sequencing over uncritical multiple-expansion optimism.
Universal Investor AI
The Polymath
GPT-6 AstraExemplary empirical rigor backed by primary filings, SEC disclosures, and statutory pricing timelines. The identification of the repatriation tax sunset as a concrete cash-retention tailwind offers exceptional analytical edge, properly balanced by sober appraisal of patent replacement burdens.
Universal Investor AI
The Polymath
Opus 5Highly credible sequencing thesis reconciling timing mismatches across cost cuts, patent expiries, and clinical pipelines. Excellent use of primary operational data and realistic treatment of metabolic competitive dynamics justify high relative weight in the consensus synthesis.
Michael Burry AI
The Vulture
Gemini 3.8 FlashThis contrarian thesis provides an indispensable stress-test of capital allocation limits, detailing how debt service and patent expiration collide with dividend commitments. While a full dividend cut remains an outlier scenario, the rigorous cash-absorption math warrants significant portfolio weighting.
Sherlock Holmes AI
The Whistleblower
Gemini 3.8 FlashThis analysis provides robust forensic balance-sheet adjustments, correctly separating non-cash trial impairment charges from recurring operating cash flow. However, its terminal valuation assumptions rely somewhat aggressively on rapid metabolic commercialization without fully discounting intermediate competitive duopoly dynamics.
Niccolo Machiavelli AI
The Insider
Gemini 3.8 FlashIncisive analysis of governance entrenchment and regulatory lobbying dynamics. The report convincingly argues why executive leadership will prioritize dividend defense above all discretionary capital deployments, providing realistic bounds on balance-sheet flexibility through restructuring phases.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashThe report presents sound owner-earnings reasoning grounded in durable free cash flow conversion and defensive pharmaceutical demand. Its primary limitation is an overly optimistic multiple re-rating expectation that underplays refinancing friction across the debt stack in a restrictive interest rate environment.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashStrong macro-demographic synthesis and realistic appraisal of pipeline thermodynamic friction support this perspective. It appropriately captures the tension between structural cost reductions and patent expirations, though its modeled recovery curve discounts near-term volatility slightly too aggressively.
Ray Dalio AI
The Strategist
Gemini 3.8 FlashA disciplined macroeconomic framework mapping sovereign yield impacts to healthcare cash flows. The report accurately identifies operating expense rationalization as an earnings stabilizer, but assumes an unusually smooth operational transition across the patent expiration chasm.
Universal Investor AI
The Polymath
Gemini 3.8 FlashThorough balance-sheet modeling captures the interplay between manufacturing optimization programs and top-line erosion. Its valuation path is slightly tempered by an overestimation of early metabolic revenue velocity prior to pivotal Phase 3 commercial readouts.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashSolid analysis of precision oncology scaling and targeted protein degradation assets. The narrative provides clear causal mechanisms for margin preservation, though its debt-reduction timeline appears somewhat optimistic given capital expenditure commitments in clinical development.
Universal Investor AI
The Polymath
Gemini 3.8 FlashA balanced quantitative synthesis reconciling stabilized post-COVID baseline revenues with targeted manufacturing savings. It provides reliable baseline margin estimates, though its quarterly trajectory somewhat smooths out expected patent litigation and regulatory milestones.
Elon Musk AI
The Visionary
Gemini 3.8 FlashThe perspective offers valuable skepticism regarding internal drug discovery productivity and historical merger integration efficiency. Nonetheless, its long-term growth acceleration thesis relies heavily on unproven clinical milestones for newly acquired metabolic assets.
J.P. Morgan AI
The Titan
Gemini 3.8 FlashThis report details commercial oncology expansion well, especially regarding hospital distribution networks. However, its projected multiple re-rating toward historical peaks underestimates structural gross margin dilution resulting from Medicare price negotiations and generic small-molecule entry.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashZero weight is assigned due to substantial analytical correlation with preceding value frameworks, alongside an unverified claim that pending Depo-Provera multidistrict litigation presents a base-case five-billion-dollar cash drain within the primary forecast window.
Research Provenance
References & Context
This Pfizer consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher webShowing the top 15 of 118 deduplicated sources retained for this batch.
- 01Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2026 | CMScms.gov
- 02Federal Reserve Board - Federal Reserve issues FOMC statementfederalreserve.gov
- 03https://www.sec.gov/Archives/edgar/data/78003/000007800326000094/pfe-6282026xex99.htm?utm_source=openaisec.gov
- 04pfe-20260628sec.gov
- 05PFIZER INC - Form 8-K - FY2026sec.gov
- 06PFIZER INC - Form 8-K - FY2026sec.gov
- 07Press Releasewelch.senate.gov
- 08Fact Sheet: President Donald J. Trump Announces Deal with Nine Additional Pharmaceutical Manufacturers to Lower Drug Prices for Americans – The White Housewhitehouse.gov
- 09Fact Sheet: President Donald J. Trump Announces Deal with Regeneron to Bring Most-Favored-Nation Pricing to American Patients – The White Housewhitehouse.gov
- 10Pfizer's 6% Yield Masks a Fragile Dividend Story - 24/7 Wall St.247wallst.com
- 11Trump faces new pressure over his "most favored nation" drug pricing dealsaxios.com
- 12Pfizer Announces Chief Financial Officer Transitionbusinesswire.com
- 13Pfizer’s obesity bet shows 14.1% weight loss in Phase IIb trialclinicaltrialsarena.com
- 14Pfizer (PFE) earnings Q2 2026cnbc.com
- 15Pfizer's $10B monthly GLP-1 bet generates competitive weight loss in phase 2bfiercebiotech.com
And 103 more sources were used and retained in the batch inventory.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-09-30–2026-06-30, 12 periods
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.